Skip to main content

Peer Review reports

From: Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results

Original Submission
26 Feb 2021 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
14 Apr 2021 Reviewed Reviewer Report - Erdinç Sarıdoğan
22 Apr 2021 Reviewed Reviewer Report
13 May 2021 Author responded Author comments - Yutaka Osuga
Resubmission - Version 4
13 May 2021 Submitted Manuscript version 4
1 Jun 2021 Author responded Author comments - Yutaka Osuga
Resubmission - Version 5
1 Jun 2021 Submitted Manuscript version 5
7 Jun 2021 Reviewed Reviewer Report - Erdinç Sarıdoğan
9 Jun 2021 Reviewed Reviewer Report
Resubmission - Version 6
Submitted Manuscript version 6
Publishing
9 Jun 2021 Editorially accepted
21 Jun 2021 Article published 10.1186/s12905-021-01393-3

You can find further information about peer review here.

Back to article page